PL3634428T3 - Lek do zapobiegania lub leczenia infekcji rinowirusowej - Google Patents

Lek do zapobiegania lub leczenia infekcji rinowirusowej

Info

Publication number
PL3634428T3
PL3634428T3 PL18833069T PL18833069T PL3634428T3 PL 3634428 T3 PL3634428 T3 PL 3634428T3 PL 18833069 T PL18833069 T PL 18833069T PL 18833069 T PL18833069 T PL 18833069T PL 3634428 T3 PL3634428 T3 PL 3634428T3
Authority
PL
Poland
Prior art keywords
drug
prevention
treatment
rhinoviral infection
rhinoviral
Prior art date
Application number
PL18833069T
Other languages
English (en)
Inventor
Johannes STÖCKL
Guido GUALDONI
Original Assignee
Medizinische Universität Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Wien filed Critical Medizinische Universität Wien
Publication of PL3634428T3 publication Critical patent/PL3634428T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18833069T 2018-01-30 2018-12-28 Lek do zapobiegania lub leczenia infekcji rinowirusowej PL3634428T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18154088.1A EP3517117A1 (en) 2018-01-30 2018-01-30 Medicament for prevention or treatment of rhinovirus infection
PCT/EP2018/097060 WO2019149436A1 (en) 2018-01-30 2018-12-28 Medicament for prevention or treatment of rhinovirus infection
EP18833069.0A EP3634428B1 (en) 2018-01-30 2018-12-28 Medicament for prevention or treatment of rhinovirus infection

Publications (1)

Publication Number Publication Date
PL3634428T3 true PL3634428T3 (pl) 2022-03-14

Family

ID=61094293

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18833069T PL3634428T3 (pl) 2018-01-30 2018-12-28 Lek do zapobiegania lub leczenia infekcji rinowirusowej

Country Status (13)

Country Link
US (4) US11413298B2 (pl)
EP (4) EP3517117A1 (pl)
JP (3) JP7359519B2 (pl)
CN (3) CN116459265A (pl)
AU (1) AU2018406914B2 (pl)
BR (1) BR112020012869A2 (pl)
CA (1) CA3086085A1 (pl)
EA (1) EA202091199A1 (pl)
ES (2) ES2989664T3 (pl)
HU (1) HUE058250T2 (pl)
PL (1) PL3634428T3 (pl)
PT (1) PT3634428T (pl)
WO (1) WO2019149436A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3846853A1 (en) 2018-09-04 2021-07-14 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal nanoparticles and use thereof against influenza virus
IL296389A (en) * 2020-03-16 2022-11-01 Univ Texas Method of treating viral infections with hexose type monosaccharides and analogs thereof
EP4132464A1 (en) * 2020-04-11 2023-02-15 Exploration Invest Pte Ltd 2-deoxy-d-glucose for prevention and treatment of a viral disease, in particular of covid-19
WO2022023335A1 (en) 2020-07-30 2022-02-03 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal compositions and use thereof
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2577321A (en) 1949-10-29 1951-12-04 Joseph B Filger Nose drop dispenser
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4603122A (en) * 1979-08-17 1986-07-29 Blough Herbert A Antiviral agent against herpes virus infections
EP0169146A3 (en) * 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
DE8422872U1 (de) * 1984-08-01 1984-10-25 Anasco GmbH, 6200 Wiesbaden Spender zur intranasalen applikation von fluessigkeiten in form von sprays oder tropfen
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
SE9201718D0 (sv) * 1992-06-03 1992-06-03 Astra Ab Nasal spray device
US6000580A (en) 1992-06-03 1999-12-14 Astra Aktielbolag Device for dispensing preservative-free nasal sprays and similar preparations
US5643883A (en) * 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
DE19706489C2 (de) * 1997-02-19 2000-08-31 Deutsches Krebsforsch Verwendung von 2-Desoxyglucose zur Behandlung von Human-Papilloma-Virus-assoziierten Läsionen und/oder Neoplasien
CA2238460A1 (en) * 1997-05-23 1998-11-23 Imutec Pharma Inc. Immunomodulating compositions for the treatment of viral disorders
US6260549B1 (en) 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
AU2003261475B2 (en) * 1998-11-05 2006-10-26 Centre National De La Recherche Scientifique Beta-L-2'-deoxy-nucleosides for the treatment of HIV infection
CA2885596A1 (en) 2001-03-20 2002-09-26 Trudell Medical International Nebulizer apparatus with an adjustable fluid orifice
CN100572387C (zh) * 2005-12-06 2009-12-23 浙江金壳生物化学有限公司 一种制备2-脱氧-d-葡萄糖的新方法
BRPI0714046A2 (pt) * 2006-07-10 2013-04-24 Univ Ramot mÉtodos de combinaÇço para tratar cÂncer
US8957031B2 (en) * 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US20100034839A1 (en) * 2008-07-25 2010-02-11 Martha Karen Newell Methods for treating viral disorders
EP2323679A4 (en) * 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
SG10201406651PA (en) * 2009-10-22 2014-11-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
CN102178686B (zh) * 2010-01-07 2016-01-13 王慧茹 多糖相关疾病的药物和疫苗及免疫测定产品
AU2011285703B2 (en) * 2010-08-04 2016-03-10 Wisconsin Alumni Research Foundation Methods and pharmaceutical compositions for treating adverse or deleterious sequellae of traumatic brain injury
WO2012077828A1 (ja) 2010-12-08 2012-06-14 学校法人日本医科大学 炎症性サイトカインの機能を抑制する炎症性疾患治療剤
US20120238511A1 (en) * 2011-03-14 2012-09-20 University Of Southern California 2-deoxy-d-glucose formulations for prevention or treatment of neurodegenerative diseases
CA2856696C (en) 2011-11-23 2020-07-14 3B Pharmaceuticals, Inc. Antiviral formulations for herpes viral infections
ES2691083T3 (es) * 2012-04-05 2018-11-23 University Of Florida Research Foundation, Inc. Composición para el tratamiento de fibrosis quística y la inducción de secreción de iones
US9757457B2 (en) * 2013-06-25 2017-09-12 The Board Of Trustees Of The University Of Illinois Use of 2-deoxy-D-glucose to sensitize cancer cells to an agent that activates the extrinsic apoptotic pathway
WO2017023793A2 (en) * 2015-07-31 2017-02-09 The Johns Hopkins University Methods for cancer and immunotherapy using glutamine analogues, including don
US10813893B2 (en) * 2017-02-24 2020-10-27 Cellular Sciences, Inc. Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea

Also Published As

Publication number Publication date
US12011453B2 (en) 2024-06-18
US11413298B2 (en) 2022-08-16
EP3634428A1 (en) 2020-04-15
JP2023134593A (ja) 2023-09-27
CN111655267B (zh) 2023-06-20
AU2018406914B2 (en) 2024-12-19
WO2019149436A1 (en) 2019-08-08
ES2907138T3 (es) 2022-04-22
EP3988102B1 (en) 2024-09-18
JP7359519B2 (ja) 2023-10-11
CN116473982A (zh) 2023-07-25
BR112020012869A2 (pt) 2020-12-29
EP3634428B1 (en) 2022-01-26
EA202091199A1 (ru) 2020-10-19
HUE058250T2 (hu) 2022-07-28
AU2018406914A1 (en) 2020-07-02
EP3988102A1 (en) 2022-04-27
US20240316082A1 (en) 2024-09-26
ES2989664T3 (es) 2024-11-27
EP3517117A1 (en) 2019-07-31
JP2021516219A (ja) 2021-07-01
US20200397805A1 (en) 2020-12-24
CA3086085A1 (en) 2019-08-08
US20220362272A1 (en) 2022-11-17
EP4487853A1 (en) 2025-01-08
CN116459265A (zh) 2023-07-21
EP3988102C0 (en) 2024-09-18
JP2023134592A (ja) 2023-09-27
US20240316083A1 (en) 2024-09-26
PT3634428T (pt) 2022-03-22
CN111655267A (zh) 2020-09-11

Similar Documents

Publication Publication Date Title
CY2022039I2 (el) Θεραπευτικες ενωσεις χρησιμες για την προφυλακτικη ή θεραπευτικη αγωγη μολυνσης ιου ηiv
EP3904351A4 (en) FAK INHIBITOR AND COMBINATION OF ACTIVE SUBSTANCES THEREOF
EP3596061C0 (en) COMPOUNDS USEFUL FOR TREATING OR PREVENTING A PRMT5-INDUCED DISORDER
EP3691549A4 (en) BLOOD STOPPER OR RESTRICTION CUFF
PL3426250T3 (pl) Leczenie pacjenta lekiem będącym substratem CYP3A4 przeciwwskazanym do jednoczesnego podawania z silnym inhibitorem CYP3A4
HUE059827T2 (hu) VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
EP3395364A4 (en) CASPASEINHIBITOR-INTENDED MEDICAMENT FOR THE TREATMENT OR PREVENTION OF TREATMENT CAUSED BY TGF-BETA AND THE USE THEREOF
PL3600374T3 (pl) Leczenie zakażenia układu oddechowego
IL271863B (en) Compounds and use thereof for the treatment of microbial infections
DK3773558T3 (da) Kombinationsbehandling af artritisk sygdom
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
DK3720433T3 (da) Bis-cholin-tetrathiomolybdat til behandling af wilsons sygdom
PT3634428T (pt) Medicamento para prevenção ou tratamento de infeção por rinovírus
EP3659136A4 (en) AUTOMATED DISEASE EVALUATION
EP3493732A4 (en) PASSIVE SENSORS AND ASSOCIATED STRUCTURES FOR IMPLANTABLE BIOMEDICAL DEVICES
IL279745A (en) Methods for treating or preventing conformation diseases and methods for drug screening
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
IL281770A (en) Indane derivatives for use in the treatment of bacterial infection
EP3632430A4 (en) AGENTS FOR THE PREVENTION OR TREATMENT OF SPINOCERBELLARY ATAXIA
EP3856207A4 (en) TREATMENT PROCESSES
EP3790928A4 (en) Medical lubricant
IL285828A (en) Compounds for treating and preventing net associated complications
EP3733243A4 (en) METHOD OF DRUG ADMINISTRATION
LT3743043T (lt) Farmacinės kompozicijos, skirtos pooperacinio skausmo gydymui
KR101912544B9 (ko) 어큐빈을 포함하는 신경정신 질환의 예방 또는 치료용 조성물